BRCA1 as a Therapeutic Target in Sporadic Epithelial Ovarian Cancer

par Clark-Knowles, Katherine V., O'Brien, Anna M., Weberpals, Johanne I.
Publié 2010

The effect of the histone deacetylase inhibitor M344 on BRCA1 expression in breast and ovarian cancer cells

par Weberpals, Johanne I, O'Brien, Anna M, Niknejad, Nima, Garbuio, Kyla D, Clark-Knowles, Katherine V, Dimitroulakos, Jim
Publié 2011

A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies

par Goss, Glenwood D., Jonker, Derek J., Laurie, Scott A., Weberpals, Johanne I., Oza, Amit M., Spaans, Johanna N., la Porte, Charles, Dimitroulakos, Jim
Publié dans J Transl Med (2016)

Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first‐line platinum chemotherapy in high grade serous ovarian cancer

par Weberpals, Johanne I., Pugh, Trevor J., Marco‐Casanova, Paola, Goss, Glenwood D., Andrews Wright, Natalie, Rath, Prisni, Torchia, Jonathon, Fortuna, Alexander, Jones, Gemma N., Roudier, Martine P., Bernard, Laurence, Lo, Bryan, Torti, Dax, Leon, Alberto, Marsh, Kayla, Hodgson, Darren, Duciaume, Marc, Howat, William J., Lukashchuk, Natalia, Lazic, Stanley E., Whelan, Doreen, Sekhon, Harmanjatinder S.
Publié dans Cancer Med (2021)

Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, ph...

par Ledermann, Jonathan A, Oza, Amit M, Lorusso, Domenica, Aghajanian, Carol, Oaknin, Ana, Dean, Andrew, Colombo, Nicoletta, Weberpals, Johanne I, Clamp, Andrew R, Scambia, Giovanni, Leary, Alexandra, Holloway, Robert W, Gancedo, Margarita Amenedo, Fong, Peter C, Goh, Jeffrey C, O’Malley, David M, Armstrong, Deborah K, Banerjee, Susana, García-Donas, Jesus, Swisher, Elizabeth M, Cameron, Terri, Maloney, Lara, Goble, Sandra, Coleman, Robert L
Publié dans Lancet Oncol (2020)

Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma

par Oza, Amit M., Lorusso, Domenica, Aghajanian, Carol, Oaknin, Ana, Dean, Andrew, Colombo, Nicoletta, Weberpals, Johanne I., Clamp, Andrew R., Scambia, Giovanni, Leary, Alexandra, Holloway, Robert W., Gancedo, Margarita Amenedo, Fong, Peter C., Goh, Jeffrey C., O’Malley, David M., Armstrong, Deborah K., Banerjee, Susana, García-Donas, Jesus, Swisher, Elizabeth M., Cella, David, Meunier, Juliette, Goble, Sandra, Cameron, Terri, Maloney, Lara, Mörk, Ann-Christin, Bedel, Josh, Ledermann, Jonathan A., Coleman, Robert L.
Publié dans J Clin Oncol (2020)

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

par Coleman, Robert L, Oza, Amit M, Lorusso, Domenica, Aghajanian, Carol, Oaknin, Ana, Dean, Andrew, Colombo, Nicoletta, Weberpals, Johanne I, Clamp, Andrew, Scambia, Giovanni, Leary, Alexandra, Holloway, Robert W, Gancedo, Margarita Amenedo, Fong, Peter C, Goh, Jeffrey C, O’Malley, David M, Armstrong, Deborah K, Garcia-Donas, Jesus, Swisher, Elizabeth M, Floquet, Anne, Konecny, Gottfried E, McNeish, Iain A, Scott, Clare L, Cameron, Terri, Maloney, Lara, Isaacson, Jeff, Goble, Sandra, Grace, Caroline, Harding, Thomas C, Raponi, Mitch, Sun, James, Lin, Kevin K, Giordano, Heidi, Ledermann, Jonathan A
Publié dans Lancet (2017)